ImetelChat

CTI/Baxalta MF drug on full clinical hold from FDA due to possible excess mortality. bp

Fisher, the changes you cite to my reading are old news from the last November update which was exciting indeed and extended the study as you point out with the changes you also mentioned. But that happened in November. Now there is a very brief and new and to my eye nebulous update I am tying to un...

Fisher, I would like to ask your opinion on what seems like an inconsequential update noted in the 1951 Mayo study on clintrials. Just some dates have been changed but nothing substantial e.g. length of study, top line reporting etc. I can't make sense of it and why it appears warranted. Could it ha...

Good info Fisher, thanks for researching this. bp

Thanks Fisher, very interesting. Yet my own experience is that drugs are available in Europe and sometime Canada before the US. Ivarabadine being one example. bp

Fisher, thank you for keeping this board clear of the garbage that was posted here recently. I can't quite get what is to be gained by posting irrelevant ramblings that were here and have been thankfully deleted presumably by our esteemed editor (that would be you). This board will take off but it m...

Fisher, truth is I have no idea. I did just review the FDA breakthrough designation info. Many designations on the basis of small phase I or II studies. Surely the data in both of Dr. T's Sept NEJM articles should qualify. bp

Looks like about half the sites (roughly 37 out of 72) sites are now active in the Janssen MF study. Should not take long for this study to be fully enrolled. Give the rapid time to drug effect (for those in whom it occurs), one hope the timeline for data will be accelerated. This might have relevan...

MDS trial updated as of Jan 20th but no details as yet posted on clinical trials site clinicaltrials.gov This will probably update active recruiting sites. Regards, bp

Hi Fisher, today's Janssen presentation again mentioned Imetelstat for MF and MDS, nothing new but one slide did indicate MDS to be a little further along than MF, I guess because the former is a II/III trial, (as far as we know there is only one patient in it as of a few days ago!) Imetelstat is in...

I found it interesting that at the very end of the J and J conference at JPM, Alex Gorsky mentioned Imetelstat by name. You wouldn't know it though, since he mispronounced both Imetelstat AND myelofibrosis! This tells me he only knows what is reported to him and has very little in the trenches conta...

http:// www .brookings.edu/ events/2015/04/24-fda- breakthrough-therapy-criteria Couldn't post link, try it without the spaces. bp

Fellow board members, first of all nice article by Hoosier, nicely done, thorough and intelligent (as always). Good research on publicly available data (but buried in different places). Can't wait to see if anything pans out in Feb with pediatric study and with possible MM combo studies. For now I h...

Fisher, the timeline is long and there is no hint as to timing of 65 M milestone. One wonders what financial events can be anticipated in 2016, could be a long year with the time line clearly geared toward 2017 events. Only thing I see hopeful over short term is non company sponsored CNS tumor trial...

Irish has posted on YMB, I can't bring myself to post there so I will thank her here and hope she finds it. Regards, bp

Hi Fisher, good points but why title the study to include ET AND PV? Since there appeared to be effect in JAK 617V in ET and since Gs supposition in their presentations has been imet effect on progenitor cells which are "upstream" in both conditions and sice PV can also transform to AML... Well you ...

Thanks Fisher, interesting to see new patents from a company that essentially shut down its primary research facilities. Speaking of shut down, I asked Anna about the two PV patients in the ET study, they are not releasing any info. Since these are presumably JAK 617V positive (speculation) I wonder...

Ry, saw your recent "Christmas present" on the YMB. You should be posting over here! For those who did not see this Ryan's friend is in remission. Best holiday wishes, BP

HI Fisher, thanks for posting these patents. Since Geron shut down their research program I suspect these were filed long ago or from affiliated academic centers. The clinical trials site was updated as of yesterday with more sites recruiting... Irish if you read this I wonder if I could impose on y...

New patent kindly posted by mangymutt on YMB: 12/17/15 Filed New Geron Patent - Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors. Regards, bp